Japan’s Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

The newspaper warned of signs “of a slowing economy” that should have the White House “on alert” and urged the president to nix his tariffs agenda ― which economists warn will send inflation soaring ...

Keeping Toronto neighbourhoods safe is our collective responsibility. Improperly discarded needles and harm reduction supplies found in our communities have been identified as a concern. In an effort ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating moderate-to-severe bullous pemphigoid (BP). The findings were presented at the 2025 ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Mathematicians have solved a decades-old problem related to spinning a needle, in what has been hailed as one of the most important mathematical results in recent times. Once seen as “impossible ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...